Next Phase Newsletter

A global healthcare-focused impact venture capital fund affiliated with a broader healthcare innovation platform is headquartered in Asia. The firm invests equity capital into technology-enabled healthcare companies, typically deploying investments ranging from approximately $500K to $2M. The firm targets opportunities from Pre-Series A through Series B stages and seeks companies capable of delivering both measurable healthcare impact and strong financial returns. The firm invests globally, with particular interest in solutions that can scale across domestic markets as well as other emerging healthcare markets.  

The firm focuses on technologies that improve healthcare access, outcomes, and quality of care. Core investment themes include preventive healthcare and self-care solutions, healthy aging and longevity, holistic wellness, and AI-enabled hospital technologies. The firm prioritizes scalable digital health platforms, data-driven healthcare technologies, and tech-enabled services addressing systemic healthcare challenges across provider systems, hospital infrastructure, and consumer health channels.  

From a company and management team perspective, the firm seeks teams with strong operational execution, clearly defined impact objectives, and the ability to scale across diverse healthcare environments. The firm prioritizes companies with validated technologies, credible commercial models, and realistic market adoption strategies. Beyond capital, the firm provides portfolio companies with access to strategic partnerships, healthcare providers, hospital systems, and regional expansion support across Southeast Asia and other high-growth markets. The firm is open to acting as either a lead investor or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: technology, health, business, entrepreneurship, finance, investing

A venture investment arm of an international healthcare and pharmaceutical organization is focused on advancing innovative patient-centered solutions. The firm invests in early-stage life sciences companies developing breakthrough therapeutics, medical devices, digital health technologies, nutraceuticals, and medical foods. The firm prioritizes opportunities aligned with key strategic healthcare areas and supports portfolio companies through industry expertise and international commercial networks.  

The firm focuses on respiratory diseases, central nervous system and neurological disorders, and women’s health. Within women’s health, areas of particular interest include urinary tract infections, vaginal infections, and related unmet healthcare needs. The firm evaluates opportunities across therapeutics, diagnostics, digital health, medical devices, nutraceuticals, and medical foods that can improve patient access, disease management, and quality of care. The firm does not invest in oncology and generally avoids technologies designed exclusively for inpatient or hospital-only environments, preferring solutions accessible in broader patient-care settings.  

In addition to early-stage investments, the firm is open to strategic collaborations with companies that already have commercialized products and are seeking international expansion opportunities. The firm leverages the broader organization’s global infrastructure and commercial presence to support geographic growth and market access.  

From a company and management team perspective, the firm seeks teams with strong scientific or clinical expertise and a clear commitment to impactful innovation. While prior industry experience is viewed positively, the firm remains open to working with promising founders and syndicate partners aligned with its strategic focus areas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

A life sciences-focused venture capital firm with offices in Europe focuses on disruptive early-stage life sciences companies and invests primarily in therapeutics. The firm is actively investing through its latest fund and has built a portfolio of multiple startups through both direct investments and company creation initiatives. The firm invests predominantly in Europe, with a strong emphasis on opportunities in Western Europe. 
 
The firm invests primarily in therapeutics and does not currently focus on medical devices, diagnostics, or digital health. The firm is modality-agnostic and evaluates a broad range of therapeutic approaches. Areas of strongest interest include oncology, immuno-oncology, rare and orphan diseases, infectious diseases, and immunology. The firm typically invests from preclinical through early clinical stages and focuses on opportunities with the potential to become first- or best-in-class therapies. 
 
From a company and management team perspective, the firm is open to working with both experienced operators and first-time entrepreneurs and has supported several companies led by first-time CEOs. The firm places strong emphasis on diversity in leadership and maintains a hands-on investment approach, actively mentoring and supporting portfolio companies. The firm is open to acting as either a lead investor or co-investor and works closely with scientific founders, academic institutions, and syndicate partners to help companies scale and mature. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

A long-established venture capital firm based in Asia is affiliated with one of the world’s largest financial services groups. The firm invests across multiple sectors, including life sciences, and has the flexibility to deploy multi-million-dollar investments depending on the opportunity. The firm evaluates opportunities globally and is actively seeking new international investments. 

Within life sciences, the firm focuses on therapeutics and medical technologies that address significant unmet medical needs relevant to the firm’s domestic market. The firm is particularly interested in companies with clear partnership strategies involving pharmaceutical or healthcare organizations, including licensing, co-development, and strategic investment structures. The firm evaluates a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated products. The firm primarily targets programs in Phase I clinical development but may also consider opportunities approaching clinical entry within approximately one year. Areas of interest include oncology, orphan diseases, and other high unmet need indications. 

From an investment structure perspective, the firm prefers to co-invest alongside established institutional investors in opportunities outside its domestic market. As a result, the firm strongly prefers companies with a credible lead investor or an existing institutional syndicate already in place. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

A recently established investment firm based in Asia and backed by a large industrial family enterprise. The firm manages substantial capital and focuses on early-stage opportunities across life sciences and healthcare. The firm typically invests from Seed through Series B and evaluates opportunities globally. In addition to capital investment, the firm is interested in supporting international companies seeking expansion opportunities into the China market.  

The firm’s investment activity is weighted primarily toward therapeutics, while also maintaining interest in diagnostics, medical technology, and AI-enabled healthcare solutions. Within therapeutics, the firm prioritizes highly innovative, next-generation approaches rather than incremental improvements. Areas of interest include advanced drug delivery technologies for mRNA and gene-editing therapies, particularly non-traditional delivery systems and platforms capable of targeting difficult tissues such as the brain. The firm also evaluates extracellular delivery technologies and next-generation cell therapy approaches designed to improve scalability, manufacturability, and cost efficiency. Modalities of interest include TCR-based platforms, NK cell technologies, and macrophage-targeting approaches. The firm is broadly indication-agnostic and is open to technically complex programs addressing major unmet medical needs.  

The firm does not impose strict requirements regarding company structure or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

An early-stage venture capital based in the United States focuses on digital health and AI-enabled healthcare technologies designed to shift healthcare from reactive treatment toward prevention, early diagnostics, and long-term disease management. The firm invests across Pre-Seed through Series A stages using both equity and SAFE structures, with typical check sizes ranging from approximately $200K to $2M. Geographically, the firm focuses on health technology companies expanding into the U.S. market, with particular interest in companies operating on the U.S. East Coast and internationally connected healthcare startups. The firm provides hands-on go-to-market support through a broad healthcare network that assists portfolio companies with U.S. commercialization and market-entry strategy.  

The firm is interested in a wide range of digital health and AI-driven healthcare solutions. Core thematic interests include mental health and well-being, women’s health and femtech, chronic disease management, musculoskeletal health, and senior care. The firm also actively evaluates AI-powered diagnostics and clinical decision-support technologies, behavior change and patient engagement platforms, remote patient monitoring solutions with predictive capabilities, prevention and early-detection technologies, and clinically validated digital therapeutics.  

From a company and management team perspective, the firm does not impose strict requirements regarding company structure or leadership composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

 
A large multi-stage venture capital and private equity firm manages substantial assets across multiple strategies. The firm recently established a dedicated life sciences investment vehicle focused on global venture, growth-stage, and co-investment opportunities. The strategy operates in partnership with major international healthcare and investment organizations to support long-term value creation and commercialization.  

The firm invests broadly across life sciences while expanding its focus into digital healthcare and bio-IT convergence. The strongest areas of interest remain within therapeutics, particularly antibody-drug conjugates (ADC), targeted protein degradation (TPD), and cell and gene therapy. Key therapeutic areas include oncology, metabolic disorders, immunology, and neurology. The firm is also actively evaluating opportunities in AI-enabled healthcare, medical data infrastructure, synthetic biology, next-generation diagnostics, and wearable technologies.  

From a company and management team perspective, the firm prioritizes teams with strong scientific and technical expertise. The investment team includes professionals with R&D and clinical development backgrounds who conduct in-depth technical evaluations. Following investment, the firm leverages strategic global partnerships and industry networks to support commercialization, business development, and technology transfer from academic and research institutions. The firm is particularly interested in companies with strong expansion potential or opportunities positioned for strategic or early exit outcomes. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: technology, health, business, entrepreneurship, finance, investing